Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kyungsangbukdo currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and 1 distinct art unit. WILSON, MICHAEL C is the busiest examiner, with 1 pending office action.
The presence of 1 distinct art unit suggests that the company's current patent activity is specialized within a specific technical niche. Because the busiest examiner pending count of 1 matches the total pending office actions of 1, the active portfolio is currently under the review of 1 distinct examiner. This concentration means that the outcome of the company's current prosecution depends on the evaluation of this individual. Practitioners should note that with this limited workload, there is no internal baseline for comparing examiner behavior within this specific portfolio. The alignment of the assigned staff and 1 distinct art unit suggests a direct path for the company's current intellectual property efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265086 | TRANSGENIC ANIMAL HAVING MODIFIED MYOSTATIN GENE | WILSON, MICHAEL C | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265086 | TRANSGENIC ANIMAL HAVING MODIFIED MYOSTATIN GENE | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | — | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKyungsangbukdo has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael C Wilson has the most, with 1 of Kyungsangbukdo's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.